In addition, considering the role of PAK in tumor immune escape, the selective use of PAK1 inhibitors or modulators (such as siRNAs, miRNAs, LncRNAs or antibody drugs) in immunotherapy may also be a candidate for adjuvant cancer treatment. The gene discussed is PAK1; the disease is neoplasm.